Anderson E S, Powers P S
Department of Psychiatry and Behavioral Medicine, University of South Florida College of Medicine, Tampa.
J Clin Psychiatry. 1991 Mar;52(3):102-4.
Clozapine, an atypical antipsychotic drug, is indicated for severely ill schizophrenic patients refractory to treatment with conventional neuroleptics. One advertised advantage of clozapine is the absence of associated neuroleptic malignant syndrome (NMS). On the basis of a clinical case, the authors question this claim. They are concerned that this potentially fatal condition may be misdiagnosed if physicians are not aware of possible NMS associated with the use of clozapine.
氯氮平是一种非典型抗精神病药物，适用于对传统抗精神病药物治疗无效的重症精神分裂症患者。氯氮平一个宣传的优点是不会引发相关的抗精神病药物恶性综合征（NMS）。基于一个临床病例，作者对这一说法提出质疑。他们担心，如果医生没有意识到使用氯氮平可能会引发NMS，这种潜在的致命病症可能会被误诊。
